FTSE COMPANY REPORT Share price analysis relative to sector and index performance Angle AGL Pharmaceuticals and Biotechnology — GBP 1.21 at close 14 May 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 14-May-2021 14-May-2021 14-May-2021 1.3 250 160 1D WTD MTD YTD 1.2 150 Absolute 6.6 6.6 3.9 153.4 Rel.Sector 6.0 5.5 2.2 140.7 1.1 140 Rel.Market 5.4 8.0 3.1 132.0 200 130 1 120 0.9 VALUATION 110 0.8 150 100 Trailing Relative Price Relative 0.7 Price Relative 90 PE -ve 0.6 Absolute Price (local currency) (local Price Absolute 80 100 EV/EBITDA -ve 0.5 70 PB 8.3 0.4 60 PCF -ve 0.3 50 50 Div Yield 0.0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Price/Sales +ve Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.1 100 100 100 Div Payout 0.0 90 90 90 ROE -ve 80 80 80 70 Index) Share 70 Share Sector) Share - - 70 60 60 DESCRIPTION 60 50 50 50 The principal activity of the Company is 40 40 RSI RSI (Absolute) 40 commercialising a platform technology that can 30 30 capture cells circulating in blood which are related to 20 30 20 cancer diagnostics and foetal health. 10 20 10 RSI (Relative to FTSE UKFTSE All to RSI (Relative RSI (Relative to FTSE UKFTSE All to RSI (Relative 0 10 0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Past performance is no guarantee of future results. Please see the final page for important legal disclosures. 1 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Valuation Metrics Price to Earnings (PE) EV to EBITDA Price to Book (PB) 30-Apr-2021 30-Apr-2021 1 9 0.9 8 0.8 0.7 7 +1SD 0.6 6 0.5 Avg 0.4 5 0.3 4 -1SD 0.2 3 0.1 0 ‖ ‖ 2 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 PureTech Health 120.0 Oxford Biomedica 100.0 Indivior 18.6 Dechra Pharmaceuticals 120.0 Genus 36.5 AstraZeneca 8.9 Genus 81.7 Dechra Pharmaceuticals 31.5 Angle 8.3 AstraZeneca 40.9 AstraZeneca 20.8 Oxford Biomedica 8.0 Pharmaceuticals and Biotechnology 21.6 Pharmaceuticals and Biotechnology 12.7 Dechra Pharmaceuticals 6.8 Hikma Pharmaceuticals 16.8 Hikma Pharmaceuticals 11.8 Genus 6.5 GlaxoSmithKline 11.7 Vectura Group 10.9 Pharmaceuticals and Biotechnology 6.3 Vectura Group 5.5 GlaxoSmithKline 8.1 GlaxoSmithKline 4.6 Indivior -9.8 Indivior 7.9 Hikma Pharmaceuticals 3.6 Angle -27.2 PureTech Health 0.0 PureTech Health 2.4 Oxford Biomedica -120.0 Angle 0.0 Vectura Group 1.2 -150 -100 -50 0 50 100 150 0 20 40 60 80 100 120 0 2 4 6 8 10 12 14 16 18 20 Price to Cash Flow (PCF) Dividend Yield % Price to Sales (PS) 30-Apr-2021 30-Apr-2021 1 16 ‖ ‖ 0.9 14 0.8 12 0.7 0.6 10 0.5 8 0.4 6 0.3 4 0.2 0.1 2 0 0 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Oxford Biomedica 80.0 GlaxoSmithKline 6.0 Angle 15.0 Genus 48.5 Pharmaceuticals and Biotechnology 3.7 PureTech Health 15.0 Dechra Pharmaceuticals 40.8 AstraZeneca 2.7 Oxford Biomedica 10.2 AstraZeneca 27.0 Hikma Pharmaceuticals 1.5 Dechra Pharmaceuticals 8.5 Vectura Group 26.9 Dechra Pharmaceuticals 0.9 Genus 6.0 Hikma Pharmaceuticals 16.8 Genus 0.6 AstraZeneca 4.9 Pharmaceuticals and Biotechnology 15.8 Vectura Group 0.0 Vectura Group 3.5 GlaxoSmithKline 8.8 PureTech Health 0.0 Pharmaceuticals and Biotechnology 3.2 Indivior -7.5 Oxford Biomedica 0.0 Hikma Pharmaceuticals 3.1 PureTech Health -11.6 Indivior 0.0 Indivior 2.2 Angle -36.0 Angle 0.0 GlaxoSmithKline 2.0 -60 -40 -20 0 20 40 60 80 100 0 1 2 3 4 5 6 7 0 2 4 6 8 10 12 14 16 Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 2 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Valuation Metrics Net Debt to Equity Dividend Payout (DP) Return on Equity (RoE) 30-Apr-2021 30-Apr-2021 0.061 1 0.9 0.9 0.05 0.8 0.8 0.7 +1SD 0.7 0.04 0.6 0.6 0.030.5 0.5 0.4 0.4 0.02 0.3 Avg 0.3 0.2 0.2 0.01 0.1 0.1 0 ‖ ‖ ‖ ‖ 0 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Indivior 3.5 AstraZeneca 100.0 GlaxoSmithKline 44.2 GlaxoSmithKline 1.9 Dechra Pharmaceuticals 100.0 Pharmaceuticals and Biotechnology 31.8 Pharmaceuticals and Biotechnology 1.5 Pharmaceuticals and Biotechnology 80.5 Vectura Group 25.4 AstraZeneca 1.3 GlaxoSmithKline 69.3 AstraZeneca 23.2 Dechra Pharmaceuticals 0.6 Genus 46.7 Hikma Pharmaceuticals 21.1 Hikma Pharmaceuticals 0.4 Hikma Pharmaceuticals 26.7 Genus 8.0 Genus 0.3 Vectura Group 0.0 Dechra Pharmaceuticals 5.9 Oxford Biomedica 0.1 PureTech Health 0.0 PureTech Health 0.9 PureTech Health 0.1 Oxford Biomedica 0.0 Oxford Biomedica -6.6 Angle 0.1 Indivior 0.0 Angle -39.4 Vectura Group 0.0 Angle 0.0 Indivior -50.0 0 0.5 1 1.5 2 2.5 3 3.5 4 0 20 40 60 80 100 120 -60 -40 -20 0 20 40 60 ROE vs. PB — sector Du Pont Analysis 20 2 1.2 18 INDV 0 1 16 -2 14 -4 0.8 12 -6 0.6 PB 10 -8 AZN AGL 8 OXB -10 0.4 DPH GNS Pharmaceuticals 6 -12 GSK 0.2 4 HIK -14 PRTC 2 -16 0 VEC 2017 2018 2019 2020 2021 0 0 5 10 15 20 25 30 35 40 45 50 Net Margin Asset Turnover Gearing ROE (rhs) ‖ ROE Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 3 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Brief description Brief description Price to Earnings Price to Earnings (PE) is price over earnings per share. Earnings are based on the latest Gearing Gearing is Total Assets divided by Common Equity. Total Assets and Common Equity are (PE) available fiscal year earnings. each averaged over two years, that is, t and (t-1). Price to Sales (PS) Price to Sales (PS) is price divided by sales per share. It is based on sales from continuing Asset Turnover Asset turnover is Sales divided by Total Assets. Total Assets is averaged over two years, operations for the fiscal year. that is, t and (t-1). Price to Book (PB) Price to Book (PB) is price at the indicated date divided by common equity per share. Dupont Breakdown Return on Equity (RoE) = Net Margin * Gearing * Asset Turnover Common/ordinary equity is generally as reported at the most recent fiscal year-end but is Analysis adjusted to exclude minority interest, preferred stock and selected items as appropriate. RoE vs PB Plot of RoE versus PB at last month end for all FTSE UK All Share stocks in the sector Price to Cash Flow Price to Cash Flow (PCF) is price at the indicated date divided by cash flow per share. relative to the stock in question. Data may be limited to the stock in question if there are (PCF) currently no stocks in the corresponding FTSE UK All Share sector. Net Debt Equity Net Debt Equity is Net Debt as a percentage of common equity. Not calculated if Absolute Absolute graphs reflect performance for the stock in question for up to 366 days adjusted denominator (common equity) is negative for intervening corporate actions. EV to EBITDA EV to EBITDA is Enterprise Value divided by EBITDA (Earnings before Interest and Taxes, Relative Relative charts reflect the performance for the stock in question relative to the depreciation and amortisation). EV is full company Market Capitalisation at the data date corresponding sector of the FTSE All Share Index for up to 366 days, rebased to the start plus last annual net debt and Preferred Stock. Net Debt is total financial debt less cash date. Note that the stock itself may not be a FTSE All share constituent. Relative Chart and short-term investments. EBITDA is operating income plus depreciation and may be null if there are no stocks in the corresponding FTSE UK All Share sector. amortisation. RSI Relative Strength Index.